Disc Medicine's bitopertin meets all main goals in Phase 3 trial
Oct 20, 2026
Disc Medicine (NASDAQ: IRON), a US biotechnology company, announced on Monday, October 19, 2026 that its drug bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial in erythropoietic protoporphyria (EPP).
What EPP is
EPP is a rare inherited condition in which a substance called protoporphyrin IX (PPIX) builds up in the body. When people with EPP are exposed to sunlight, they can experience severe pain, which limits the time they can spend outdoors. Bitopertin is taken by mouth once a day and is designed to reduce the production of PPIX.
The results
The APOLLO trial included 183 patients aged 12 and older in the United States, Canada, Europe and Australia, who received bitopertin or a placebo for six months. According to Disc:
- bitopertin reduced whole-blood PPIX levels by 41.4% compared with placebo
- average monthly pain-free time in light increased by 12.2 hours compared with placebo at month six
- secondary measures, including the rate of phototoxic reactions and cumulative pain-free time in light, also improved
- the most common side effect was dizziness, reported in 50% of patients, which was generally mild or moderate and short-lived; the company reported no new safety signals
Both main results were statistically significant. These are topline results announced by the company, and the full data have not yet been published.
Regulatory background
In February 2026, the US Food and Drug Administration (FDA) declined to grant accelerated approval to bitopertin, saying that earlier trials had not clearly shown that lower PPIX levels led to better tolerance of sunlight. The FDA indicated that a successful Phase 3 trial could support a standard approval. Disc said it plans to resubmit its application by the end of 2026, with an FDA decision expected by mid-2027.
About bitopertin
Bitopertin was originally developed by Roche and tested in schizophrenia, where it did not succeed. Disc licensed the drug from Roche and is developing it for blood disorders. Disc focuses on diseases related to red blood cells and iron, which is reflected in its stock ticker.
Why it matters
There are few treatment options for people with EPP. A successful trial in a rare disease can be important for a small biotechnology company, as one product can make up most of its potential value. At the same time, approval is not guaranteed, and the FDA will review the full data.
How the FDA review process works
When the FDA declines to approve a drug, it issues a complete response letter explaining what is needed. A company can then resubmit its application with new data. The FDA sets a target date for its decision, which is usually several months after the resubmission is accepted. During the review, the agency may ask for more information or hold a meeting of outside experts.
Rare disease treatments
Treatments for rare diseases can receive special status from regulators, such as orphan drug designation, which can provide incentives including periods of market exclusivity. Because patient numbers are small, trials in rare diseases are often smaller than those for common conditions.
What to watch
Key items for the coming months include the full presentation of the APOLLO data, the timing of the resubmission to the FDA, the FDA's review and Disc's plans for commercial launch.
Risks and uncertainties
Clinical trial results reported by companies are preliminary until full data are published and reviewed by regulators. The FDA may not approve the drug, or may approve it with restrictions. Shares of small biotechnology companies can be highly volatile.
What this means for investors
For Investing.one users following IRON, the Phase 3 results and the planned resubmission to the FDA may be relevant. The information above is based on the company's announcement and published reports.
Sources
This is not investment advice. Your capital is at risk.
www.investing.one is solely and exclusively operated by Tradeplace Limited (Registration number HE 434666). Tradeplace Limited is authorised and regulated by the Cyprus Securities and Exchange Commission (License number 455/25).
The information on this website is general in nature. Please consider the information in light of your objectives, financial situation and needs.
When investing, your capital is at risk and you may get back less than invested. Past performance doesn't guarantee future results.
We do not establish accounts to residents outside of the EU/EEA area. For further details please see the Client Agreement - Terms and Conditions. For privacy and data protection related complaints and information on handling personal data please refer to our Privacy Policy.
